Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
Kyverna Therapeutics stock last closed at $14.00, down 4.11% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Biotechnology industry by N/A percentage points. Kyverna Therapeutics stock is currently +14.19% from its 52-week low of $12.26, and -60.07% from its 52-week high of $35.06.
There are currently 43.12M shares of KYTX outstanding. The market value of KYTX is $603.61M. In the past 24 hours, 217,579 KYTX shares were traded.
How to Buy Kyverna Therapeutics Stock
Wondering how to invest in Kyverna Therapeutics stock? Here's how.
Choose where to buy Kyverna Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Kyverna Therapeutics stock.
Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Fund your investment account: Select your payment method and add your information.
Evaluate Kyverna Therapeutics stock: The Kyverna Therapeutics ticker symbol is KYTX. Is Kyverna Therapeutics stock a good investment? Should you buy shares of KYTX? How do KYTX's underlying business fundamentals look? Do top analysts think Kyverna Therapeutics is a good buy? Why has KYTX's stock price moved recently? (Hint: Our stock research tools can help you understand if KYTX is a good stock to buy).
Execute your KYTX purchase: Decide if you will purchase KYTX shares at the current market price or use a limit order to buy KYTX stock at a particular price.
Watch your investment in KYTX: Create a watchlist to track your investment in Kyverna Therapeutics shares.
Step 1: Choose where to buy Kyverna Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy KYTX stock.
A brokerage account allows you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our experience, eToro is the best stock brokerage. Here's why:
You can invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to global markets: From Technology to Energy, New York to Hong Kong — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal details so you are able to buy KYTX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Kyverna Therapeutics stock
After you have figured out the best place to buy Kyverna Therapeutics stock, it's very important to analyze their stock before you buy, so you truly understand the risk as well as the upside.
Kyverna Therapeutics Numbers
KYTX Price
$14.00
1w %
-8.2%
1y %
N/A
5y %
N/A
P/E
-0.16x
P/B
-4.59x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$60.37M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$603.61M
Next Earnings
N/A
Next Dividend
N/A
Fundamentals of Kyverna Therapeutics
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis in less time.
Last year, KYTX revenue was $0.00. Over the last two year, KYTX's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 31.46%.
In the past year, executives and large shareholders at KYTX have bought more shares than they have sold.
Bain Capital Life Sciences Investors LLC, 10% Owner of KYTX, was the latest KYTX insider to buy. They bought $9,900,000.00 worth of KYTX shares on Feb 12, 2024.
No, Kyverna Therapeutics doesn't provide an income stream by paying out dividends.
KYTX Social Trading Data
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your KYTX purchase
You have two primary order types:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are usually the best for newer investors.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a specific price, place a limit order.
Hit the Open Trade button and your broker will execute your order.
If you want additional help with investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Kyverna Therapeutics share?
As of May 10, 2024, it costs $14.00 to buy one share of Kyverna Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $7, you can buy 0.5 shares of KYTX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.